Objective: MicroRNAs have emerged as a new class of non-coding genes involved in regulating cell proliferation, differentiation and viability. Recent studies have identified miR-210 as one of a set of hypoxia-regulated microRNAs and demonstrated a direct regulatory role of HIF-1 alpha for its transcription. Here, we assessed miR-210 expression in Japanese triplenegative breast cancers and determined its clinical significance. Methods: TaqMan MicroRNA assays for miR-210 expression were performed on 161 samples of Japanese breast cancer tissue (58 triple-negative breast cancer and 103 estrogen receptor positive/HER2 negative). Correlations between miR-210 expression and clinicopathological factors were analyzed. The effects of several variables on survival were tested by a Cox proportional hazards regression analysis. Results: miR-210 expression in triple-negative breast cancers was significantly higher than in estrogen receptor-positive/HER2-negative breast cancers (P , 0.001). Patients whose triplenegative breast cancers showed low miR-210 expression experienced significantly better disease-free and overall survival than those with high miR-210 expression (P ¼ 0.02 and P ¼ 0.05, respectively). Although the prognosis of patients with triple-negative breast cancers is poor, Cox univariate and multivariate analyses demonstrated that a higher expression of miR-210 was an independent factor indicating a worse prognosis than for patients with a low level of miR-210. Conclusions: The degree of miR-210 expression might be a clinically useful prognostic factor for decision-making regarding treatment in the adjuvant setting, especially in nodenegative triple-negative breast cancer patients.
Estrogen receptor (ER) α is essential for estrogen-dependent growth, and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα-positive breast cancer. Breast cancer patients show a wide range of ERα expression levels and the levels of expression in individual patients change during disease progression and in response to systemic therapies. However, little is known about how the expression of ERα in human breast cancer is regulated. Recently, several microRNAs (miRNAs) that directly target ERα have been identified, and we previously demonstrated that miR-206 expression was downregulated in ERα-positive human breast cancer. In this study, expression levels of miRNAs that directly target ERα, including miR-18a, miR-18b, miR-22, miR-193b, miR-221/222 and miR-302c, were analyzed in human breast cancer samples by quantitative reverse transcription-PCR analysis. Correlations between the expression levels of these miRNAs and clinicopathological factors, including prognosis, were analyzed. miR-18a expression was much higher in ERα-negative than in ERα-positive tumors (P < 0.0001), with the expression levels of miR-18a not differing in ERα-positive breast cancer as a function of ERα protein level. Surprisingly, the expression levels of miR-193b and miR-221 were significantly lower in ERα-negative than in ERα-positive tumors (P = 0.0015 and P = 0.0045, respectively), and the levels of these miRNAs gradually increased as ERα protein expression increased. There was no statistically significant association between miR-22 and ERα expression, and miR-302c expression was minimal in human breast cancer samples. Prognostic analysis showed that low miR-18b expression was significantly associated with improved survival in HER2-negative breast cancer, although miR-18b expression was not correlated with ERα protein expression. Our results suggest that miRNAs that directly target ERα have distinct roles in not only regulating ERα but also regulating other target genes in human breast cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.